Aflibercept May Be Effective for Resistant Exudative AMD

Source: Medscape

Thursday, June 15, 2017 | Medical Studies , Retina


Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report. "Our two-year data show that a treat-and-extend (T-and-E) protocol using aflibercept is a reasonable strategy for treatment-resistant wet AMD patients,” Dr. Oystein Kalsnes Jorstad from Oslo University Hospital and the University of Oslo, Norway, told Reuters Health by email. “Many cases need 4-6 weeks’ injection intervals in order to achieve a dry macula.”

Open in New Window

Comments

You must be logged in to leave a comment.